Skip to main content

InspireMD, Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

NSPR$0.78+9.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(U.S. dollars in thousands)

20262025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(28,013)$(24,317)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation307205
Change in fair value of marketable securities, net of interest received-(155)
Change in liability for employee rights upon retirement248277
Other financial income(18)(58)
Change in operating right of use asset and operating leasing liability64377
Share-based compensation expenses4,3235,940
Gains on amounts funded in respect of employee rights upon retirement, net(84)(95)
Changes in operating assets and liability items:
Decrease in prepaid expenses198113
Decrease (increase) in trade receivables352(20)
Decrease (increase) in other receivables(192)186
Decrease (increase) in inventory695(484)
Increase in trade payables399264
Increase (decrease) in other payables(1,511)642
Net cash used in operating activities(23,232)(17,125)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment(524)(935)
Investments in marketable securities-(11,749)
Proceeds from matured marketable securities30,00019,760
Amounts funded in respect of employee rights upon retirement(44)(52)
Net cash provided by investing activities29,4327,024
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants-1,947
Proceeds from issuance of shares, net of $22 issuance costs-696
Net cash provided by financing activities-2,643
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS1051
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS6,210(7,407)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD8,93918,916
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD$15,149$11,509
SUPPLEMENT NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance Costs not yet paid-109
Acquisition of right-of-use assets by means of lease liabilities-994
Non-cash purchase of property and equipment57-
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.